Intrinsic Imaging
Gastroenterologist in front of abdominal CT, MR enterography, and endoscopy monitors

Gastroenterology & Metabolic Imaging Division

Intrinsic Imaging provides imaging core lab services in support of gastroenterology and metabolic clinical trials. Sponsors draw on our subspecialty gastroenterologists, central endoscopy review and quantitative abdominal imaging to assess safety and efficacy in gastrointestinal, hepatobiliary, pancreatic, metabolic, renal and related abdominal and pelvic indications.

At Intrinsic Imaging, our Gastroenterology Imaging division brings together more than 35 board-certified, fellowship-trained gastroenterologists with expertise across a broad range of acute and chronic gastrointestinal conditions, including inflammatory bowel disease, ulcerative colitis, gastroesophageal reflux disease (GERD), short bowel syndrome, and gastrointestinal ulcerative disease. In these and other complex disorders, imaging and endoscopic evaluation can provide objective evidence of disease activity, progression, and therapeutic response.

Intrinsic Imaging supports gastroenterology endpoints across a comprehensive range of imaging and diagnostic modalities, including CT and high-resolution CT, low-dose and advanced CT techniques, MRI, endoscopy, and nuclear imaging with quantitative methodologies. Our teams work closely with sponsors from protocol development and imaging charter design through regulatory-ready data delivery to develop study-specific imaging strategies, qualify sites and readers, standardize acquisition, maintain image and endoscopy quality control, and conduct centralized independent review with quantitative assessment and adjudication.

By combining experienced gastroenterology specialists with disciplined central-review processes and consistent assessment methodologies, Intrinsic Imaging helps sponsors minimize inter-site and inter-reader variability across longitudinal timepoints, an essential consideration when imaging or endoscopic findings contribute to efficacy, safety, disease-activity, or exploratory biomarker endpoints. This scientific, clinical, and operational expertise supports complex gastroenterology clinical development programs from early-phase investigation through pivotal trials.

Gastroenterology Imaging Division Highlights

  • Extensive experience in providing services in support of clinical trials involving the GI system.
  • 35+ board-certified and fellowship-trained gastroenterologists.
  • Experience in imaging of organ specific endocrine disorders as well as multiple endocrine syndromes and neoplasia.
  • Modality expertise includes:
    • CT including novel techniques
    • Endoscopy
  • High Resolution CT imaging and low dose techniques.
    • MRI
    • Nuclear imaging with quantitative techniques

Central Endoscopy and GI Imaging Review

At Intrinsic Imaging, our GI imaging and endoscopy core lab provides centralized independent review of endoscopy and imaging for inflammatory bowel disease, ulcerative colitis, GERD, short bowel syndrome, ulcerative disease, and other gastrointestinal and abdominal disorders. Central review gives sponsors an objective assessment of disease activity and consistent, reproducible data across multicenter and global clinical trials.

CT, MRI and Quantitative Nuclear Imaging

Intrinsic Imaging supports high-resolution and low-dose CT, advanced CT techniques, MRI, endoscopy, and nuclear imaging with quantitative methodologies. Study-specific acquisition standards and image and endoscopy quality control keep each examination suitable for the assessment the protocol requires.

Consistent Assessment Across Sites and Timepoints

Intrinsic Imaging minimizes inter-site and inter-reader variability in efficacy, safety, disease-activity, and exploratory biomarker endpoints through site and reader qualification, adjudication, and consistent methodology across longitudinal timepoints.

IBD, Liver Disease and Quantitative Abdominal Imaging

GI studies often combine endoscopy, cross-sectional imaging, and tissue assessment. Intrinsic Imaging defines each assessment separately and coordinates their acquisition, independent review, and data delivery around the protocol, allowing sponsors to manage these endpoints through a single core lab.

Study focusMethodsCentral assessment
Crohn’s diseaseIleocolonoscopy and MR enterographySES-CD, CDEIS and MaRIA or simplified MaRIA, as specified by the protocol
Ulcerative colitisEndoscopyMayo endoscopic subscore and UCEIS
Steatotic liver disease and MASHMRI-PDFF and MR elastographyLiver fat fraction and stiffness, with acquisition and analysis controls
Liver fibrosisMR or ultrasound elastographyProtocol-defined stiffness measurements and longitudinal change
GI tissue endpointsDigital pathology and histopathology reviewProtocol-defined tissue scores, including Robarts or Nancy indices where applicable
Abdominal disease and GI tumorsCT, MRI, ultrasound and nuclear imagingAnatomic, functional and lesion-based imaging measures

Central Endoscopy Scoring and Video Quality

Intrinsic Imaging’s site instructions define required segments, video recording, mucosal visualization, and labeling, and central quality control confirms that each recording is complete and supports the selected score. Our gastroenterologists qualify on representative cases and apply blinded review and adjudication rules to reduce variation between sites and readers.

MR Enterography and Crohn’s Disease Activity

Intrinsic Imaging’s MR enterography protocols address bowel preparation, distension, coverage, and required sequences, and readers evaluate wall thickening, edema, enhancement, and ulceration using the protocol’s MaRIA-based method. Imaging scores are kept distinct from endoscopic and clinical activity measures, with clear rules for segment matching and missing assessments, giving sponsors an independent imaging measure of disease activity.

Liver Fat, Stiffness and Tissue Endpoints

Intrinsic Imaging measures liver fat by MRI proton density fat fraction (MRI-PDFF) using standardized acquisition and region selection, and evaluates stiffness by MR elastography with quality checks for wave propagation and measurement reliability. Fat fraction and stiffness describe different tissue properties and are assessed as separate measures, not as interchangeable indicators of fibrosis or clinical outcome.

When a study includes histopathology, Intrinsic Imaging keeps specimen handling and tissue scoring in a separate pathology workflow. Imaging and tissue results can then be reconciled at the study-data level without compromising reader blinding.

Emerging Indication Spotlight: MASH Trials and MRI-PDFF

Metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH) has become one of the most active areas of drug development, and noninvasive imaging now plays a central role in screening, enrichment, and treatment monitoring. Intrinsic Imaging supports MASH trials with MRI-PDFF, which quantifies hepatic fat across the whole liver and reduces the sampling limitations of a single biopsy core, and with MR elastography, which adds a measure of liver stiffness relevant to fibrosis staging.

Intrinsic Imaging standardizes multi-echo acquisition across scanner vendors and field strengths, defines region-of-interest placement and segmentation rules, and qualifies sites with test submissions before enrollment. Longitudinal analysis reports absolute and relative fat-fraction change at protocol-defined timepoints, with quality flags for motion, iron overload, and other confounding factors. Imaging results are delivered for integration with histology and clinical endpoints as the protocol specifies.

Guidance for Sponsors

Physician-authored guidance from Intrinsic Imaging on imaging endpoints and trial design.

Illustration of the human liver

Guidance for Sponsors · Volume 4, Issue 1 · 2026 Edition

Magnetic Resonance Elastography: A Quantitative Endpoint for Liver Fibrosis Trials

Magnetic resonance elastography (MRE) measures liver stiffness without a needle, and it has become one of the most accurate imaging tools available for staging liver fibrosis. Now that the FDA has approved the first therapies for metabolic dysfunction-associated steatohepatitis (MASH), sponsors developing the next generation of liver therapies need endpoints that are quantitative, repeatable and acceptable to patients. Combined with MRI proton density fat fraction (MRI-PDFF) in a single liver MRI exam, MRE provides exactly that: a one-minute acquisition that stages fibrosis and tracks how it changes over the course of a trial.

Read the article
Illustration of tumor cells

Guidance for Sponsors · Volume 5, Issue 1 · 2026 Edition

Immunotherapy and Imaging of Metastatic Pancreatic Adenocarcinoma

Pancreatic adenocarcinoma remains one of the most lethal cancers, with a five-year relative survival of 13% and a rising share of U.S. cancer deaths. After a decade in which checkpoint immunotherapy largely failed in this disease, the therapeutic landscape is finally changing: a new first-line chemotherapy regimen has been approved, and in 2026 an oral RAS inhibitor doubled overall survival in a Phase 3 trial of previously treated patients. These advances raise the stakes for imaging. Contrast-enhanced CT, MRI and FDG-PET/CT must deliver staging and response data that are standardized, reproducible and interpretable under the right criteria, including iRECIST when immunotherapy is involved.

Read the article
Illustration of the colon with a red tumor mass in the sigmoid region representing colorectal cancer

Guidance for Sponsors · Volume 6, Issue 8 · 2026 Edition

Metastatic Colorectal Cancer and Locoregional Therapies

The American Cancer Society estimates about 158,850 new cases of colorectal cancer and 55,230 deaths in the United States in 2026, and the disease is now the leading cause of cancer death in adults under 50.[1] Roughly half of patients develop liver metastases, and for most of them the liver is what determines survival. Over the past decade the options for treating those metastases have multiplied: systemic therapy guided by molecular profiling, radioembolization, chemoembolization with drug-eluting beads, thermal ablation and, remarkably, liver transplantation. Each produces imaging changes that conventional size-based criteria handle poorly. This issue reviews the current evidence and what sponsors should build into trials of liver-directed therapy.

Read the article

More guidance: Tissue Iron MRI Quantitation in Trials

Browse all Guidance for Sponsors →

Featured Case Study

Intrinsic Imaging

Gastroenterology & Metabolic

Phase IIb Inflammatory Bowel Disease Trial

  • Crohn's disease and ulcerative colitis
  • Endoscopy video, MR enterography
  • SES-CD and Mayo Endoscopic Score

Challenge

In inflammatory bowel disease trials, endoscopic and cross-sectional assessments of disease activity are inherently interpretive. When scoring is performed at individual sites, that subjectivity translates directly into variability: the same endoscopic finding may be scored differently by different investigators, and eligibility decisions can diverge accordingly. The sponsor needed to reduce this inconsistency from both the screening process and the SES-CD and Mayo Endoscopic Score assessments that anchored the trial's efficacy evaluations.

Read the case study
View all case studies

Frequently Asked Questions

Which therapeutic areas does Intrinsic Imaging support?
Intrinsic Imaging’s therapeutic expertise encompasses Cardiovascular & Thoracic, Central Nervous System, Gastroenterology & Metabolic, Musculoskeletal, Oncology and Ophthalmology. Intrinsic Imaging’s subspecialty physicians assess images according to the acquisition methods, response criteria and biomarkers specified for each study.
Is GAMP 5 a regulation or a certification?
No. GAMP 5 is ISPE’s good-practice guidance for a risk-based lifecycle approach to compliant GxP computerized systems; it is neither a regulation nor a certification. GAMP 5 does not confer FDA approval or supersede applicable regulations. Intrinsic Imaging’s five ISO certifications are distinct from this validation framework.
Does Intrinsic Imaging read OCT and fundus autofluorescence?
Yes. Intrinsic Imaging reviews OCT and fundus autofluorescence alongside color fundus photography, fluorescein angiography and adaptive optics imaging.
Go to more Frequently Asked Questions

Tell us about your trial.

Planning a Gastroenterology trial? Our team will respond within one business day.